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Metabolism of primaquine in normal 
human volunteers: investigation of phase 
I and phase II metabolites from plasma 
and urine using ultra-high performance liquid 
chromatography-quadrupole time-of-flight 
mass spectrometry
Bharathi Avula1, Babu L. Tekwani1* , Narayan D. Chaurasiya1, Pius Fasinu1, N. P. Dhammika Nanayakkara1, 
H. M. T. Bhandara Herath1, Yan‑Hong Wang1, Ji‑Yeong Bae1, Shabana I. Khan1, Mahmoud A. Elsohly1, 
James D. McChesney2, Peter A. Zimmerman3, Ikhlas A. Khan1 and Larry A. Walker1
Abstract 
Background: Primaquine (PQ), an 8‑aminoquinoline, is the only drug approved by the United States Food and Drug 
Administration for radical cure and prevention of relapse in Plasmodium vivax infections. Knowledge of the metabo‑
lism of PQ is critical for understanding the therapeutic efficacy and hemolytic toxicity of this drug. Recent in vitro 
studies with primary human hepatocytes have been useful for developing the ultra high‑performance liquid chroma‑
tography coupled with high‑resolution mass spectrometric (UHPLC‑QToF‑MS) methods for simultaneous determina‑
tion of PQ and its metabolites generated through phase I and phase II pathways for drug metabolism.
Methods: These methods were further optimized and applied for phenotyping PQ metabolites from plasma and 
urine from healthy human volunteers treated with single 45 mg dose of PQ. Identity of the metabolites was predicted 
by MetaboLynx using LC–MS/MS fragmentation patterns. Selected metabolites were confirmed with appropriate 
standards.
Results: Besides PQ and carboxy PQ (cPQ), the major plasma metabolite, thirty‑four additional metabolites were 
identified in human plasma and urine. Based on these metabolites, PQ is viewed as metabolized in humans via three 
pathways. Pathway 1 involves direct glucuronide/glucose/carbamate/acetate conjugation of PQ. Pathway 2 involves 
hydroxylation (likely cytochrome P450‑mediated) at different positions on the quinoline ring, with mono‑, di‑, or even 
tri‑hydroxylations possible, and subsequent glucuronide conjugation of the hydroxylated metabolites. Pathway 3 
involves the monoamine oxidase catalyzed oxidative deamination of PQ resulting in formation of PQ‑aldehyde, PQ 
alcohol and cPQ, which are further metabolized through additional phase I hydroxylations and/or phase II glucuron‑
ide conjugations.
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Primaquine (PQ), an 8-aminoquinoline, is the only drug 
approved by the US FDA for treatment and radical cure 
of relapsing Plasmodium vivax malaria [1]. The World 
Health Organization (WHO) has recently recommended 
use of a single low dose of primaquine for mass drug 
administration programmes for control and elimination 
of Plasmodium falciparum malaria [2], primarily due to 
action of PQ against mature P. falciparum gametocytes 
and prevention of malaria transmission [3]. Clinical util-
ity of PQ has also been indicated for treatment of other 
infectious diseases, namely leishmaniasis, trypanosomia-
sis and pneumocystis pneumonia [4]. However, the use 
of PQ has been restricted due to toxic effects, especially 
haemolytic toxicity in individuals with genetic deficiency 
of glucose-6-phosphate dehydrogenase (G6PD) [5, 6]. 
G6PD deficiency is the most common enzymopathy with 
more than > 400 million cases world-wide [7, 8] and it 
is more prevalent in the malaria endemic areas [9]. The 
anti-malarial activity and toxicity of PQ have been attrib-
uted to one, or more, of its metabolites [10–12]. PQ is 
rapidly metabolized to the carboxyprimaquine (cPQ) by 
oxidative deamination [13]. Phenolic metabolites of PQ 
have long been suggested as potential haemotoxic spe-
cies [12]. The oxidation products have been identified as 
metabolites of PQ in the biological fluids of experimen-
tal animals treated with PQ. These putative hydroxylated 
metabolites have been observed to cause oxidative dam-
age to normal and G6PD-deficient erythrocytes [14–17].
Recent experimental studies with primary human 
hepatocytes [13, 18–20] and the recombinant human 
enzymes (CYPs and amine oxidases) [12, 21] have been 
useful in phenotyping of key PQ metabolites and their 
relative quantification. The results have been utilized 
for prediction of pathways for metabolism of PQ [12, 
18, 22]. Metabolism of PQ has been presumed to fol-
low two distinct pathways. A major pathway is thought 
to be initiated by oxidative deamination of PQ to cPQ 
[18, 23]. Carboxy PQ is further metabolized through 
CYP mediated pathways and phase II metabolism, gen-
erating quinone-imine metabolites and glucuronide 
conjugates [18, 22]. This pathway has been suggested 
to determine characteristic pharmacokinetic and phar-
macodynamic properties of PQ [13, 24–27]. Another 
pathway, mediated through CYPs (predominantly 
CYP2D6), generates multiple hydroxylated metabolites 
[21]. CYP2D6-mediated oxidation of PQ occurs at dif-
ferent positions on the quinoline ring. PQ-5,6-ortho 
quinone was identified as the major CYP2D6 metabo-
lite, formed by degradation of the unstable 5-hydroxy-
PQ [21]. Most of the previous studies on clinical 
pharmacokinetics and metabolism of PQ have been 
limited to quantification of parent drug PQ and cPQ 
(the major plasma metabolite) [13, 23–27]. This study 
extends the investigation to other phase I and phase II 
metabolites of PQ from plasma and urine of normal 
human volunteers treated with a single dose of PQ 
(45 mg).
The diverse analytical methods focused on PQ or its 
analogues have so far targeted pharmacokinetic studies 
and metabolite analyses [28–30] or isomer separation/
characterization [31]. The methods employing ultra-high 
performance chromatography coupled with high-resolu-
tion mass spectrometry offer significant advantages over 
other analytical methods including high speed and sen-
sitivity. This approach was recently employed for pheno-
typing PQ metabolites generated in  vitro on incubation 
of stable isotope (13C) labelled PQ with primary human 
hepatocytes [18, 20] or recombinant human CYP2D6 
[21]. This approach was useful in developing UHPLC-
QToF-MS method for simultaneous analysis of PQ and 
its metabolites in biological samples. This method has 
been further optimized for the analysis of PQ metabolites 
in human plasma and urine.
Methods
Chemicals and materials
Acetonitrile and methanol of HPLC-grade were obtained 
from Fisher Scientific (Fair Lawn, NJ, USA). Water 
was purified in a Milli-Q system (Millipore, Bedford, 
MA, USA). Primaquine diphosphate and formic acid 
were purchased from Sigma (St Louis, MO, USA). Car-
boxyprimaquine (cPQ) was prepared using the procedure 
reported by McChesney and Sarangan [32]. Primaquine 
alcohol, 2-hydroxyprimaquine, 3-hydroxyprimaquine, 
4-hydroxyprimaquine, 5-hydroxyprimaquine, pri-
maquine-5,6-ortho-quinone, primaquine N-carbamoyl 
Conclusion: This approach and these findings augment our understanding and provide comprehensive view of 
pathways for PQ metabolism in humans. These will advance the clinical studies of PQ metabolism in different popula‑
tions for different therapeutic regimens and an understanding of the role these play in PQ efficacy and safety out‑
comes, and their possible relation to metabolizing enzyme polymorphisms.
Keywords: Primaquine, Antimalarial, Malaria, Plasmodium vivax, 8‑aminoquinoline, Drug metabolism, UHPLC‑
QToF‑MS, Cytochrome  P450
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glucuronide, primaquine methyl carbamate, carboxy 
primaquine lactam, carboxy primaquine methyl ester 
and primaquine N-acetate were synthesized at National 
Center for Natural Products Research (NCNPR) and 
their identity and purity were confirmed by spectral data 
(IR, NMR and High-Resolution MS) and comparison of 
their physical data (m.p.) with published values [20, 21].
Subjects, treatment, samples collection
The study was conducted with seven healthy adult 
human volunteers (age 26–51 years). The information on 
age, sex and ethnicity of individual human volunteers are 
provided in a previous report [13]. The individuals were 
orally administered three tablets of primaquine phos-
phate (equivalent to a total dose of 45  mg primaquine 
base) (Sanofi-Aventis US), 30 min after a normal break-
fast. Blood samples were collected in 9  mL heparin 
 vacutainer® tubes at different time intervals, ranging 
from 30  min to 24  h, after administration of PQ. The 
tubes with blood samples were immediately processed 
for centrifugation under refrigerated conditions (4  °C) 
and separation of plasma and erythrocytes pellet. The 
urine samples from each individual were collected before 
treatment and up to 24 h after the treatment. The plasma 
and urine samples from individual volunteers were 
divided into aliquots, kept on dry ice and transferred for 
storage at − 80  °C till further analysis. The aliquots of 
plasma and urine samples were processed and analysed 
using UHPLC-QToF-MS for analysis and phenotyping 
the PQ metabolites as described below.
Sample preparation
Plasma sample preparation: Aliquots of 500  μL plasma 
samples from PQ treated normal human volunteers, 
stored at − 80  °C, were thawed on ice. The plasma was 
treated with 1 mL chilled methanol, vortexed and stored 
overnight at − 80 °C. The samples were withdrawn from 
the freezer, vortexed and kept in an ultrasonic water 
bath for 10 min. Later they were centrifuged for 10 min 
at 14,000  rpm. The clear supernatants were transferred 
to fresh tubes, evaporated to dryness in a vacuum cen-
trifuge and individually reconstituted with 200 μL chilled 
HPLC grade methanol. The samples were transferred to 
HPLC sample vials for analysis.
Urine sample preparation
Aliquots of 10  mL of urine samples were freeze-dried. 
The dried samples were reconstituted with 1 mL chilled 
HPLC grade methanol. The samples were kept on an 
ultrasonic water bath, vortexed and centrifuged at 
14,000  rpm for 10  min. The clear supernatants were 
transferred to fresh vials and subjected to analysis.
Metabolite identification using UHPLC‑QToF‑MS
The UHPLC-QToF-MS analytical method and other con-
ditions were as described in earlier publications from us 
[20, 21]. Plasma and urine samples were analysed using a 
Waters Acquity UPLC™ system (Waters Corp., Milford, 
MA, USA) coupled to a Xevo Q-ToF mass spectrometer. 
Chromatographic separations were achieved using BEH 
C18 column (2.1  mm × 100  mm, 1.7  μm) at a flow rate 
of 0.25  mL/min. MS conditions were optimized in the 
positive electrospray mode with the instrumental param-
eters. Ten microlitre of sample was injected. PQ and 
metabolites were assigned with respect to the mass of 
the compounds and comparison of the retention times. 
This method involved the use of [M + H]+ ions of the 
compound PQ which was observed in the positive ion 
mode at m/z 260.1774 (calculated m/z = 260.1763) and 
for PQ metabolites (carboxyprimaquine, 2-hydroxypri-
maquine, 3-hydroxyprimaquine, 4-hydroxy-primaquine, 
primaquine N-carbamoyl glucuronide, primaquine 
methyl carbamate, carboxy primaquine lactam, carboxy 
primaquine methyl ester and primaquine N-acetate). 
Prior to performing all experiments, the instrument was 
calibrated in positive ionization mode over a 50-1000 Da 
mass range, using a 2 µg/µL solution of sodium formate 
dissolved in methanol. This solution produces singly 
charged reference ions in both ion modes and is ideal as 
a calibrant for low molecular weight analysis. Further, 
the fragmentation patterns observed in the mass spec-
trum were useful in characterization of the compound. 
MetaboLynx™ processing software (Waters Corp., Man-
chester, UK) was used to assist molecular ion detection 
and a combination of accurate mass and MS/MS data on 
the molecular ions was used for structural identification 
of individual metabolites.
Results
The PQ metabolites in plasma and urine were identified 
based on the retention time, HR-MS and MS/MS frag-
mentation patterns of individual metabolites. The forma-
tion and identity of metabolites were supported by their 
accurate mass and fragmentation pattern. The chemi-
cal structures of these metabolites were predicted by the 
MetaboLynx XS, a software algorithm for metabolite 
prediction, based on their MS–MS fragmentation ions 
as described below and other associated information 
(Table 1) (Additional file 1). The proposed fragmentation 
patterns and other associated information for PQ and 
other metabolites provided information about their struc-
tural skeleton. Besides PQ (m/z 260.1769) (15) and cPQ 
(m/z 275.1385) (33) (Table 1), thirty-four PQ metabolites, 
whose structures could be determined with MS/MS frag-
mentation ions, were detected in the plasma and urine 
samples. MS/MS fragmentation profiles for the selected 
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metabolites, determined with confidence, are presented in 
the supplement data (Additional file 1). Molecular charac-
teristics of individual metabolites are described below and 
also are presented in Table 1. The metabolites are listed in 
order of their retention time and detection in both plasma 
& urine, only in plasma and only in urine.
Table 1 HR-MS data for primaquine and its metabolites from human plasma and urine samples
a Observed mass of the metabolite (calculated mass is shown in parenthesis)
# RT (min) Exact mass Peaka [M + H]+ Molecular Formula Biotransformation
(Metabolite Predicted/Identified)
Sample/source
1 3.5 273.1477 274.1549 (274.1550) C15H19N3O2 Hydroxylation and quinone‑imine formation Plasma/urine
2 4.97 259.1679 260.1769 (260.1757) C15H21N3O Precursor ion (PQ)
3 5.3 256.1206 257.1273 (257.1285) C15H16N2O2 Oxidative deamination to acid + cyclization (Carboxypri‑
maquine lactam)
4 7.98 479.1898 480.1992 (480.1977) C22H29N3O9 Carbamoyl glucuronide formation (PQ‑N‑carbamoyl‑
glucuronide conjugate)
5 8.95 274.1312 275.1385 (275.1390) C15H18N2O3 Deamination + Acid (Carboxyprimaquine)
6 10.12 288.1468 289.1560 (289.1547) C16H20N2O3 Deamination + Acid + Methylation (Carboxyprimaquine 
methyl ester)
7 4.67 421.2207 422.2315 (422.2286) C21H31N3O6 Glucose conjugation Plasma
8 6.03 320.1367 321.1454 (321.1445) C16H20N2O5 (Deamindation + acid) + 2xOH + methylation (dihydroxy 
carboxyprimaquine methyl ester)
9 9.65 317.1734 318.1789 (318.1812) C17H23N3O3 Methyl carbamate formation (PQ methyl carbamate)
10 1.78 259.1315 260.1403 (260.1399)* C14H17N3O2 5‑Hydroxylation +Orthoquinone formation (5,6 orthoqui‑
none primaquine)
Urine
11 1.9 451.1955 452.2011 (452.2027) C21H29N3O8 Hydroxylation + Glucuronide conjugation
12 2.2 421.1849 422.1908 (422.1922) C20H27N3O7 5‑Demethylation + Glucuronidation (5‑desmethyl PQ 
glucuronide)
13 2.32 451.1955 452.2011 (452.2027) C21H29N3O8 Hydroxylation + Glucuronide conjugation
14 2.34 275.1634 276.1712 (276.1707) C15H21N3O2 Hydroxylation (4‑OH PQ)
15 3.1 452.1795 453.1881 (453.1868) C21H28N2O9 Deamination + alcohol + hydroxylation + glucuronidation
16 3.12 315.1947 316.2002 (316.2020) C18H25N3O2 Methylation + Acetylation
17 3.45 275.1634 276.1694 (276.1707) C15H21N3O2 Hydroxylation
18 3.85 275.1634 276.1697 (276.1707) C15H21N3O2 Hydroxylation (2‑OH PQ)
19 4.43 245.1528 246.1617 (246.1601) C14H19N3O Demethylation
20 4.88 493.206 494.2127 (494.2133) C23H31N3O9 Acetylation + (Hydroxylation + Glucuronide conjugation)
21 4.92 275.1634 276.1705 (276.1707) C15H21N3O2 Hydroxylation (3‑OH PQ)
22 5.18 273.1477 274.1534 (274.1550) C15H19N3O2 Hydroxylation and quinone‑imine formation
23 5.67 483.1853 484.1932 (484.1926) C21H29N3O10 3 x Hydroxylation + 1 x glucuronide conjugation
24 5.9 289.1426 290.1500 (290.1499) C15H19N3O3 2 x Hydroxylation + quinone‑imine formation
25 5.92 291.1583 292.1647 (292.1656) C15H21N3O3 2 x hydroxylation
26 6.15 498.1486 499.1545 (499.1559) C21H26N2O12 Deamination + acid + 3 x hydroxylation + 1 x glucuronide 
conjugate
27 6.17 466.1587 467.1666 (467.1660) C21H26N2O10 (Hydroxylation + glucuronide conjugation) + (deamina‑
tion + acid)
28 6.4 291.1583 292.1647 (292.1656) C15H21N3O3 2 x hydroxylation
29 7.27 301.179 302.1875 (302.1863) C17H23N3O2 Acetylation
30 7.6 435.2006 436.2100 (436.2078) C21H29N3O7 Glucuronide conjugation
31 7.74 436.1846 437.1909 (437.1918) C21H28N2O8 Oxidative deamination to alcohol + glucuronide conjuga‑
tion
32 7.79 450.1638 451.1714 (451.1711) C21H26N2O9 (Deamination + acid) + glucuronide conjugation
33 8.2 276.1474 277.1552 (277.1547) C15H20N2O3 Deamination + alcohol + hydroxylation
34 8.6 435.2006 436.2100 (436.2078) C21H29N3O7 Glucuronide conjugation
35 8.65 315.1583 316.1676 (316.1656) C17H21N3O3 Acetylation + hydroxylation + quinone‑imine formation
36 10.38 302.1267 303.1324 (303.1339) C16H18N2O4 Deamination + acid + methylation + hydroxylation + qui‑
none‑imine formation
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Primaquine quinone‑imine (1,22)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 274.1549 [M + H]+, corresponds to the molecu-
lar formula  C15H20N3O2. Key fragments detected by 
274 peak in the LC-QToF-MS spectra are 260.1365 
[M + H-CH2], 243.1127 [M + H-CH3O]+, 241.1363 
[M + H-H3NO]+, 145.0547 [M + H-C6H13N2O]+ 
and 86.0964 [M + H-C10H8N2O2]+ (Additional file  1) 
(Table  1). Based on retention time, accurate mass and 
fragmention ions, these metabolites were predicted as a 
PQ quinone-imine, likely to be generated by hydroxyla-
tion of PQ and then dehydrogenation (Fig. 2). Identifica-
tion of two PQ quinone-imine metabolites with identical 
MS/MS profile and different retention times likely indi-
cates hydroxylation at different positions on the qui-
nolone ring.
Primaquine (2)
ESI-HRMS of PQ in plasma and urine gave a molecular 
ion peak at m/z 260.1769 [M + H]+ which corresponded 
to the molecular formula  C15H22N3O. The MS/MS spec-
trum of precursor ion, PQ showed fragments at m/z 
243.1521 (−17; –NH3, loss of ammonia) confirming the 
presence of amino group in the molecule, 175.0867 (−85; 
–C5H11N), 86.0974 (−174; –C10H10N2O) (Additional 
file 1) (Table 1) and was identical to the MS/MS of syn-
thetic PQ with the same retention time.
Carboxy‑primaquine lactam (3)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 257.1273 [M + H]+ which corresponds to the 
molecular formula  C15H17N2O2. Key fragments detected 
by 257.1273 peak in the LC-QTOF-MS spectra are 
239.1151 [M + H-H2O]+, 175.0867 [M + H-C5H6O]+, 
83.0474 [M + H-C10H10N2O]+ (Additional file  1) 
(Table 1). The metabolite is likely to be formed by oxida-
tive de-amination of PQ followed by cyclization of the 
aldehyde form and was identical to the MS/MS of syn-
thetic carboxy-primaquine lactam with the same reten-
tion time (Fig. 3).
Primaquine N‑carbamoyl glucuronide (4)
ESI-HRMS of this metabolite gave a molecular ion peak at 
m/z 480.1992 [M + H]+ which corresponds to the molec-
ular formula  C22H29N3O9. Key fragments detected by 
480 peak in the LC-QToF-MS spectra are m/z 436.2118 
[M + H-CO2]+, 304.1658 [M + H-C6H8O6]+, 260.1767 
[M + H-C7H8O8]+, 243.1500 [M + H-C7H11NO8]+, 
175.0877 [M + H-C12H19NO8]+, 86.0972 [M + H-C7H8O
8C10H10N2O]+ (Additional file 1) (Table 1). This metabo-
lite is likely to be formed due to the carbamoylation of 
PQ followed by glucuronide formation and was identical 
to the MS/MS of synthetic primaquine N-carbamoyl glu-
curonide with the same retention time (Fig. 1).
Carboxyprimaquine (5)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 275.1385 [M + H]+ which corresponded to the 
molecular formula  C15H19N2O3. The side chain of PQ 
undergoes biotransformation to PQ-aldehyde (oxidative 
deamination) and then converted to an acid (carboxypri-
maquine, cPQ) by an aldehyde dehydrogenase. Key frag-
ments detected by cPQ are 257.1306 [M + H-H2O]+ 
(intense peak), 175.0842 [M + H-C5H8O2]+, 101.0593 
[M + H-C10H10N2O]+, 83.0493 [M + H-C10H12N2O2]+ 
(Additional file  1) (Table  1). The MS/MS spectrum of 
precursor ion carboxy primaquine showed five fragment 
ions and was identical to the MS/MS of synthetic cPQ 
with the same retention time. This metabolic pathway for 
cPQ is presented in Fig. 3.
Carboxy primaquine methyl ester (6)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 289.1560 [M + H]+ which corresponds to 
the molecular formula  C16H21N2O3. The biotransfor-
mation is due to methyl carbamate formation. Key frag-
ments detected by m/z 289 peak in the LC-QToF-MS 
spectra are m/z 257.1287 [M + H-CH3OH]+, 175.0843 
[M + H-C6H10O2]+, 83.048 [M + H-C11H14N2O2]+ 
(Additional file 1) (Table 1). Formation of this metab-
olite is likely to occur through formation of PQ-alde-
hyde (oxidative deamination) followed by conversion 
to an acid (carboxy primaquine) and subsequent meth-
ylation (Fig.  3). The LC–MS/MS profile of this 
metabolite was identical to the MS/MS of synthetic 
carboxyprimaquine methyl ester with the same reten-
tion time.
Primaquine‑glucose conjugate (7)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 422.2315 [M + H]+ which corresponded to the 
molecular formula  C21H32N3O6. The MS/MS spec-
trum of precursor ion PQ-glucose showed fragments at 
m/z 404.2209 (−18; –H2O), 260.177 (−162; –C6H10O5), 
243.1523 (−179; –C6H13NO5), 175.0895 (−247; –
C11H21NO5), 86.0959 (−336; –C16H20N2O6) (Additional 
file 1) (Table 1), and was identical to the MS/MS of syn-
thetic PQ-glucose with the same retention time. The bio-
transformation is due to PQ conjugation with a glucose 
moiety (Fig. 1).
Dihydroxy‑carboxy primaquine methyl ester (8)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 321.1454 [M + H]+ which corresponds to the 
molecular formula  C16H21N2O5 (Table 1). This metabolite 
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was detected in very low quantities and the identity could 
not be established with confidence. Tentative identity 
was predicted as dihydoxy-carboxy primaquine methyl 
ester, generated through double hydroxylations on the 
quinolone ring followed methylation at side chain car-
boxy group (Fig. 3).
Primaquine methylcarbamate (9)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 318.1789 [M + H]+ which corresponds to the 
molecular formula  C17H24N3O3. Key fragments detected 
by m/z 318 peak in the LC-QToF-MS spectra are m/z 
175.0853 [M + H-C7H13NO2]+ (intense peak), 160.0619 
[M + H-C8H16NO2]+, 88.0384 [M + H-C14H18N2O]+ 
(Additional file 1) (Table 1). This metabolite is likely to be 
generated by carbamoylation of PQ followed by methyl 
carbamate formation and was identical to the MS/MS of 
synthetic primaquine methylcarbamate with the same 
retention time (Fig. 1).
Primaquine‑5,6‑ortho‑quinone (10)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 260.1403 [M + H]+ which corresponds to the 
molecular formula  C14H18N3O2. Key fragments detected 
by 260 peak in the LC-QToF-MS spectra of all samples are 
243.1134 [M + H-NH3]+, 215.1166 [M + H-CH3NO]+, 
175.0508 [M + H-C5H11N]+ (intense peak), 147.0553 
[M + H-C6H11NO]+, 86.0970 [M + H-C9H6N2O2]+ 
(Additional file 1) (Table 1). The metabolite is generated 
by hydroxylation of PQ, followed by the quinone-imine 
formation, with further oxidation and effective loss of the 
methyl group at the 6 position (Fig. 2). It was identical to 
the MS/MS of synthetic primaquine-5,6-ortho-quinone 
with the same retention time.
Hydroxy‑primaquine glucuronide (11, 13)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 452.2011 [M + H]+ (Table  1) which corresponds 
to the molecular formula  C21H30N3O8. Based on reten-
tion time, accurate mass and fragment ions, this metabo-
lite was predicted as hydroxy-primaquine glucuronide 
likely to be generated by hydroxylation, followed by glu-
curonide conjugation of PQ (Fig. 2). Identification of two 
metabolites with identical MS/MS profile but different 
retention times indicates hydroxylation at different posi-
tions on the quinoline ring.
Fig. 1 Pathway for human metabolism of PQ—pathway 1: direct metabolism of PQ through phase II conjugation reactions
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Desmethyl‑primaquine‑O‑glucuronide (12)
ESI-HRMS of this metabolite gave a molecular ion peak at 
m/z 422.1908 [M + H]+ which corresponds to the molec-
ular formula  C20H28N3O7. Key fragments detected by 
m/z 422 peak in the LC-QToF-MS spectra of all samples 
are 405.1536 [M + H-CH5]+, 246.1606 [M + H-C6H8O6]+, 
229.1341 [M + H-C6H10NO6]+, 86.0970 
[M + H-C15H16N2O7]+, 69.0704 [M + H-C15H19N3O7]+ 
(Additional file  1) (Table  1). This metabolite was tenta-
tively identified as desmethyl-primaquine-O-glucuron-
ide based on accurate mass and fragments ions and was 
likely to be generated due to demethylation and glucuro-
nide conjugation of PQ (Fig. 2).
Monohydroxy‑primaquine (14, 17, 18, 21)
ESI-HRMS of these four metabolites gave identi-
cal molecular ion peak at m/z 276.1712 [M + H]+ 
which corresponds to the molecular formula 
 C15H22N3O2. Key fragments detected by 276 peak in 
the LC-QToF-MS spectra of all samples are 259.1447 
[M + H-NH3]+, 191.0821 [M + H-C5H11N]+, 86.0970 
[M + H-C10H10N2O2]+ (Additional file 1) (Table 1). The 
three monohydroxy PQ metabolites are generated due 
to hydroxylation of PQ and were identical to the MS/
MS of synthetic hydroxy-PQs namely, 4-hydroxy PQ 
(14), 2-Hydroxy PQ (18) and 4-hydroxy PQ (19) with 
the same retention time (Table  1) (Fig.  2). The exact 
identity, regarding position of hydroxylation on the 
Fig. 2 Pathway for human metabolism of PQ—pathway 2: metabolism of PQ through phase I ring hydroxylations followed by phase II conjugations
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quinoline ring, of fourth monohydroxylated PQ metab-
olite (17) could not be established due to non-availabil-
ity of corresponding synthetic standard.
Hydroxy‑primaquine‑alcohol‑glucuronide (15)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 453.1881 [M + H]+ which corresponds to the 
molecular formula  C21H29N2O9. (Table 1). This metabo-
lite was detected in very low quantities and the identity 
could not be established with confidence. Tentative iden-
tity was predicted as hydroxy-primaquine-alcohol-glucu-
ronide. This metabolite is predictably generated through 
hydroxylation of PQ alcohol followed by glucuronide 
conjugation (Fig. 3).
Acetylated N‑methyl primaquine (16)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 316.2002 [M + H]+ which corresponds to the 
molecular formula  C18H26N3O2 (Table  1). This metabo-
lite was detected in very low quantities and the identity 
could not be established with confidence. Tentative iden-
tity was predicted as acetylated N-methyl primaquine. 
This metabolite is predictably generated through meth-
ylation of PQ and followed by acetylation (Fig. 1).
6‑desmethyl‑primaquine (19)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 246.1617 [M + H]+ which corresponded 
to the molecular formula  C14H20N3O. Key fragments 
detected by m/z 246 peak in the LC-QToF-MS spectra 
are 229.1293 [M + H-NH3]+ (intense peak), 161.0751 
[M + H-C5H11N]+, 86.0966 [M + H-C9H8N2O]+, 69.0721 
[M + H-C9H11N3O]+ (Additional file  1) (Table  1). The 
metabolite was tentatively identified as 6-desmethyl PQ 
based on accurate mass and fragments ions. Demethyla-
tion of 6-methoxy group in PQ is likely to generate this 
6-hydroxy metabolite of PQ (Fig. 2).
Fig. 3 Pathway for human metabolism of PQ—pathway 3: metabolism of PQ through oxidative deamination 8‑N alkylamino side chain followed by 
phase I ring hydroxylations and/or phase II conjugations
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Acetylated hydroxy‑primaquine glucuronide conjugate 
(20)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 494.2127 [M + H]+ which corresponded 
to the molecular formula  C23H32N3O9. Key frag-
ments detected by m/z 494 peak in the LC-QToF-MS 
spectra are 318.1797 [M + H-C6H8O6]+, 191.0805 
[M + H-C13H21NO7]+, 128.1067 [M + H-C16H18N2O8]+ 
and 86.0989 [M + H-C18H20N2O9]+ (Additional file  1) 
(Table  1). The metabolite was tentatively identified as 
acetylated hydroxy-primaquine glucuronide conjugate 
based on accurate mass and fragments ions and may be 
generated through PQ acetylation followed by monohy-
droxylation and conjugation with glucuronide moiety 
(Fig. 1).
Trihydroxy‑primaquine glucuronide (23)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 484.1932 [M + H]+ (Table 1) which corresponds to 
the molecular formula  C21H30N3O10. This metabolite was 
detected in very low quantities and the identity could not 
be established with confidence. Tentative identity was 
predicted as trihydroxy-primaquine glucuronide (Fig. 2). 
The positions for tri hydroxylations on the quinoline ring 
could not be established due to non-availability of cor-
responding synthetic standards and very low quantity of 
the metabolite.
Dihydroxy‑primaquine quinone‑imine (24)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 290.1500 [M + H]+ (Additional file  1) 
(Table  1) which corresponds to the molecular formula 
 C15H20N3O3. Key fragments detected by m/z 290 peak in 
the LC-QToF-MS spectra are 273.1194 [M + H-NH3]+, 
205.0590 [M + H-C5H11N]+, 191.0481 [M + H-C6H13N]+, 
86.0955 [M + H-C10H8N2O3]+. The metabolite was ten-
tatively identified as dihydroxy-primaquine quinone-
imine based on accurate mass and fragments ions. This 
metabolite may be generated through two hydroxylations 
of primaquine, followed by oxidation to quinone imine 
(Fig. 2). The positions of hydroxylations in this metabolite 
could not be established due to non-availability of corre-
sponding synthetic standards.
Dihydroxy‑primaquine (25, 28)
ESI-HRMS of these metabolites gave a molecu-
lar ion peak at m/z 292.1647 [M + H]+ (Addi-
tional file  1) (Table  1) which corresponds to the 
molecular formula  C15H22N3O3. Key fragments detected 
by m/z 292 peak in the LC-QToF-MS spectra are 
275.1396 [M + H-NH3]+, 207.0770 [M + H-C5H11N]+, 
87.1040 [M + H-C10H9N2O3]+. The two metabolites were 
tentatively identified as dihydroxy-primaquine based on 
accurate mass and fragments ions. These metabolites 
may be generated through two hydroxylations of pri-
maquine (Fig. 2). The positions of hydroxylations in the 
individual metabolites could not be established due to 
non-availability of corresponding synthetic standards.
Trihydroxy‑carboxyprimaquine glucuronide (26)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 499.1545 [M + H]+ which corresponded 
to the molecular formula  C21H27N2O12. Key frag-
ments detected by 499 peak in the LC-QToF-MS 
spectra are 290.0903 [M + H-C7H13O7]+, 273.0875 
[M + H-C7H14O8]+, 217.1076 [M + H-C11H10N2O7]+, 
85.0653 [M + H-C16H18N2O11]+ (Additional file  1) 
(Table  1). This metabolite was tentatively identified as 
trihydroxy-carboxyprimaquine glucuronide based on 
accurate mass and fragments ions. This metabolite may 
be generated through three hydroxylations of carboxy 
primaquine followed by glucuronidation (Fig.  3). The 
positions of hydroxylations and site of glucuronidation in 
the individual metabolites could not be established due 
to non-availability of corresponding synthetic standards.
Hydroxy‑carboxyprimaquine glucuronide (27)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 467.1666 [M + H]+ which corresponded to the 
molecular formula  C21H27N2O10. Key fragments detected 
by 467 peak in the LC-QToF-MS spectra are 449.1560 
[M + H-H2O]+, 290.0876 [M + H-C10H11NO2]+, 273.1234 
[M + H-C6H10O7]+, 217.1076 [M + H-C11H10N2O5]+, 
191.0821 [M + H-C11H16O8]+ (Additional file 1) (Table 1). 
This metabolite was tentatively identified as hydroxy-
carboxyprimaquine glucuronide based on accurate mass 
and fragments ions. This metabolite may be generated 
through hydroxylation of carboxy primaquine followed 
by glucuronidation (Fig. 3). The position of hydroxylation 
and site of glucuronidation in the individual metabolite 
could not be established due to non-availability of corre-
sponding synthetic standard.
Primaquine acetate (29)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 302.1875 [M + H]+ which corresponded 
to the molecular formula  C17H24N3O2. Key frag-
ments detected by 302 peak in the LC-QToF-MS spec-
tra are m/z 243.1502 [M + H-C2H5NO]+, 175.0864 
[M + H-C7H13NO]+, 128.1077 [M + H-C10H10N2O]+ 
(intense peak), 86.0966 [M + H-C12H12N2O2]+ (Addi-
tional file 1) (Table 1). This metabolite may be generated 
through acetylation of PQ to PQ N-acetate (Fig.  1) and 
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was identical to the MS/MS of synthetic PQ acetate with 
the same retention time.
Primaquine glucuronide (30, 34)
ESI-HRMS of these metabolites gave a molecular ion 
peak at m/z 436.2100 [M + H]+ (Table  1), which corre-
sponded to the molecular formula  C21H30N3O7. These 
metabolites were detected in very low quantities and 
their identities could not be established with confidence. 
Tentative identity of these metabolites was predicted as 
PQ glucuronide (Fig. 1).
Primaquine alcohol glucuronide (31)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 437.1909 [M + H]+ which corresponded to the 
molecular formula  C21H29N2O8. Key fragments detected 
by PQ alcohol glucuronide in the LC-QToF-MS spectra of 
all samples are m/z 261.1598 [M + H-C6H8O6]+, 175.0868 
[M + H-C11H18O7]+, 159.0310 [M + H-C15H22N2O3]+, 
87.0810 [M + H-C16H18N2O7]+ (Additional file  1) 
(Table  1). This metabolite was tentatively identified as 
primaquine alcohol glucuronide based on accurate mass 
and fragments ions. This metabolite may be generated 
through oxidative de-amination of PQ to alcohol fol-
lowed conjugation with glucuronide moiety (Fig. 3).
Carboxyprimaquine glucuronide (32)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 451.1714 [M + H]+ which corresponds to the 
molecular formula  C21H27N2O9. Key fragments detected 
by 451 peak in the LC-QToF-MS spectra are 275.1408 
[M + H-C6H8O6]+, 257.1290 [M + H-C6H10O7]+ 
(intense peak), 175.0884 [M + H-C11H16O8]+, 101.0593 
[M + H-C16H18N2O7]+ (Additional file  1) (Table  1). This 
metabolite may be generated through glucuronide conju-
gation of carboxy PQ and was identical to the MS/MS of 
synthetic carboxyprimaquine glucuronide with the same 
retention time (Fig. 3).
Hydroxy‑primaquine alcohol (33)
ESI-HRMS of this metabolite gave a molecular ion peak at 
m/z 277.1552 [M + H]+ which corresponds to the molec-
ular formula  C15H21N2O3. Key fragments detected by 
277 peak in the LC-QToF-MS spectra are m/z 175.0871 
[M + H-C5H10O2]+, 83.0797 [M + H-C10H12NO3]+ 
(Additional file  1) (Table  1). This metabolite was tenta-
tively identified as hydroxyl primaquine alcohol based on 
accurate mass and fragments ions. This metabolite may 
be generated through oxidative de-amination of PQ to 
alcohol followed by hydroxylation (Fig. 3). However, the 
site for hydroxylation on the quinoline ring could not be 
established due to non-availability of corresponding syn-
thetic standards.
N‑Acetyl‑primaquine quinone‑imine (35)
ESI-HRMS of this metabolite gave a molecular ion peak 
at m/z 316.1676 [M + H]+ which corresponds to the 
molecular formula  C17H22N3O3. Key fragments detected 
by 316 peak in the LC-QToF-MS spectra are m/z 
302.1402 [M + H-CH2]+, 147.0922 [M + H-C8H11NO3]+ 
(Additional file 1), (Table 1). This metabolite was tenta-
tively identified as N-acetyl-primaquine quinone-imine 
based on accurate mass and fragments ions and may be 
generated through N-acetylation on the side chain and 
hydroxylation of PQ followed by oxidation to quinone-
imine (Fig. 1).
Primaquine quinone‑imine carbamate (36)
ESI-HRMS of this metabolite gave a molecular ion 
peak at m/z 303.1321 [M + H]+ which corresponds to 
the molecular formula  C16H19N2O4. Key fragments 
detected by 303 peak in the LC-QToF-MS spectra are 
m/z 287.1365 [M + H–O]+, 271.1016 [M + H-CH3OH]+, 
189.0700 [M + H-C6H10O2]+ (Additional file 1), (Table 1). 
This metabolite was tentatively identified as primaquine 
quinone-imine carbamate based on accurate mass and 
fragments ions and may be generated through methyla-
tion, hydroxylation and quinone imine formation of car-
boxy PQ (Fig. 3).
Plasma PQ metabolite profile
Very limited numbers of PQ metabolites were detected 
in plasma from the individuals treated with single dose 
of PQ. Besides PQ (m/z 260.1769) (2) and cPQ (m/z 
275.1385) (5), only seven additional metabolites of PQ 
were detected in plasma. These include four phase I 
metabolites namely, hydroxy-primaquine quinone-imine 
(m/z 274.1549) (1), carboxyprimaquine lactam (m/z 
257.1273) (3), Dihydroxy-carboxyprimaquine methyl-
ester (m/z 321.1454) (8) and carboxyprimaquine methyl 
ester (m/z 289.1560) (6) and three phase II metabolites, 
namely, glycosylated PQ (m/z 422.2315) (7), PQ N-carba-
moyl glucuronide (m/z 480.1992) (4) and PQ methyl car-
bamate (m/z 318.1789) (9). No hydroxylated metabolites 
of PQ were detected in plasma.
Urine PQ metabolite profile
The urine from the individuals treated with PQ contained 
large numbers of PQ metabolites. PQ (m/z 260.1769) (2) 
and the major plasma metabolite cPQ (m/z 275.1385) 
(5) were detected in urine also. Besides these, the car-
boxy PQ lactam (m/z 257.1273) (3), predictably formed 
by spontaneous cyclization of carboxy side chain of cPQ 
and PQ carbamoyl glucuronide (m/z 480.1992) (4), a 
unique phase II metabolite formed through direct N-car-
bamoylation of PQ followed by glucuronidation, which 
were present in plasma, were also detected in urine. 
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Glycosylated PQ (m/z 422.2315) (7), a prominent metab-
olite detected in plasma, was not detected in urine. Three 
acetylated metabolites were present in urine namely, PQ 
acetate (m/z 302.1875) (29), acetylated hydroxyl-PQ glu-
curonide conjugate (m/z 494.2127) (20) and N-Acetyl-
PQ quinone-imine (m/z 316.1676) (35). Two metabolites 
with different retention times but identical accurate mass 
and MS/MS fragmentation profile corresponding to PQ 
glucuronide conjugate (m/z 436.2100) (30, 34) were also 
detected in urine.
Surprisingly, four mono hydroxylated metabolites of 
PQ, likely to be formed through CYP mediated path-
ways, were detected in urine. Three of these metabolites 
(m/z 276.1694) correspond to 2-OH (18), 3-OH (21), 
and 4-OHPQ (14), and the fourth (17) could be 7-OH, 
8-N–OH, 1-N-oxide, or 8-N-oxide of PQ. Desmethy-PQ 
(m/z 246.1606) (19), and desmethyl-PQ glucuronide (m/z 
422.1908) (12) were also detected in urine. Two metab-
olites predicted as PQ-quinone-imine (m/z 274.1549) 
(1, 22) and PQ-5,6-ortho-quinone (m/z 260.1403) (10), 
which is spontaneously generated from 5-OH-PQ, were 
also detected in urine. None of these phase I metabo-
lites were detected in plasma. Further metabolism of 
hydroxyl-PQ was evident from presence of two dihy-
droxy-PQ (m/z 292.1647) metabolites (25, 28) and a 
dihydroxyl PQ quinone-imine (m/z 290.15) (24). Phase II 
conjugation metabolites, generated from further metabo-
lism of hydroxyl PQ metabolites, detected in urine were 
two monohydroxy-PQ glucuronides (m/z 452.2011) (11, 
13) trihydroxy-PQ glucuronide (m/z 484.1932) (23) and 
desmethyl-PQ glucuronide (m/z 422.1908) (12).
Further metabolism of cPQ, a major plasma metabo-
lite, through phase I and phase II pathways of drug 
metabolism was evident from presence of several cPQ 
metabolites namely, cPQ glucuronide (m/z 451.1722) 
(32), hydroxyl cPQ glucuronide (m/z 467.1649) (27), 
trihydroxy-cPQ glucuronide (m/z 499.1545) (26) and 
dihydroxy cPQ methylester (m/z 321.1454) (8). Hydroxy-
PQ alcohol (m/z 277.1559) (33), PQ alcohol glucuronide 
(m/z 437.1911) (31), hydroxyl-PQ alcohol glucuronide 
(m/z 453.1881) (15) detected in urine may be generated 
through further metabolism of PQ alcohol, the metabo-
lite from oxidative deamination of PQ side chain alkyl 
amine.
Discussion
Both therapeutic efficacy and toxicity of PQ have been 
attributed to its metabolites, likely generated through 
CYP mediated pathways of drug metabolism [10, 12]. 
Understanding of metabolism of PQ is highly critical for 
determining the mechanism of toxicity and efficacy of 
this drug [11, 12]. PQ has high value for global malarial 
control and eliminations efforts, due to its broad utility 
for treatment including radical cure, prophylaxis and pre-
vention of malaria transmission [1–3, 33].
Based on the comprehensive LC-ESI-HRMS and MS/
MS fragmentation profiles of PQ metabolites identi-
fied in plasma and urine of healthy human volunteers 
treated with single dose of 45 mg, PQ may be regarded 
as metabolized broadly through three pathways. Path-
way 1 involves direct glucuronide/glucose/carbamate/
acetate conjugation of PQ. The presence of N-carbamoyl 
glucuronide conjugate of PQ, both in plasma as well as 
in urine, indicates direct conjugation of PQ without its 
metabolism through phase I pathway. Generation of this 
metabolite involves N-carbamoylation of PQ by carba-
moyltransferases, followed by glucuronide conjugation 
by UDP-glucuronosyltransferases (UGTs) [34]. Although 
this pathway is not widely appreciated in drug metabo-
lism, a few drugs containing primary or secondary 
amines have been reported to undergo N-carbamoylation 
and glucuronidation [35, 36]. Incubation of such drugs 
with UGT under high  CO2 tension yield N-carbamoyl 
glucuronide conjugates [36]. Mechanisms of this reac-
tion involving human carbamoyltransferases and UGTs 
have not been identified yet. Metabolism of PQ through 
this pathway may be an important determinant for 
steady state concentration and overall pharmacokinetic-
pharmacodynamics profiles of the drug. It was recently 
reported formation of N-carbamoyl glucuronide conju-
gate of PQ as a predominant metabolite, when PQ was 
incubated in vitro with primary human hepatocytes [20]. 
Formation of this metabolite in vitro with human hepato-
cytes was enantioselective, as (+)-S-PQ generated more 
than two-fold higher levels of the conjugate than (−)-R-
PQ [20]. This may simply reflect the higher susceptibil-
ity of (−)-R-PQ to the oxidative deamination pathway 
[13]. Glycosylated PQ, another unexpected phase II PQ 
metabolite detected in plasma only, was also reported 
to form in  vitro with primary human hepatocytes [20] 
and was more prominently formed from (+)-S-PQ than 
from (−)-R-PQ. In the human hepatocyte study, glyco-
sylated PQ was detected at time zero and thought to be 
a simple adduct of the primary amine group of PQ and 
the aldehyde form of glucose via non-enzymatic means. 
This metabolite could also be formed in plasma by the 
same mechanism. Predominant metabolism of (+)-S-PQ 
through these pathways may explain the somewhat lower 
plasma concentrations of the (+)-S-PQ, despite its negli-
gible metabolism through oxidative deamination to cPQ 
[13, 20].
The pathway 2 (Fig.  2) involves hydroxylation of PQ 
at different positions on the quinoline ring, forming 
mono-, di- and even tri-hydroxylated species, and sub-
sequent conjugation of these ring hydroxylated metabo-
lites to glucuronic acid. Surprisingly, none of the ring 
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hydroxylated metabolites, 6-desmethyl PQ, or their glu-
curonide conjugates were detected in plasma. This may 
be due to rapid excretion of these metabolites in urine. 
It is interesting that the presumed active/toxic metabo-
lite PQ-5,6-orthoquinone was only detected in urine but 
not in plasma. Recent PK and tissue distribution stud-
ies in mice showed rapid appearance of PQ-5,6-ortho-
quinone in high concentrations in the liver and in low 
concentration in plasma and its fast disappearance from 
the liver and circulation [37]. Formation of ring hydroxy-
lated metabolites have also been demonstrated in  vitro 
on incubation of PQ with primary human hepatocytes 
[20] and recombinant human CYP2D6 [21]. CYP2D6 
and PQ incubations generated considerably high levels 
of ring hydroxylated PQ metabolites and 5,6-orthoqui-
none PQ. Earlier in vitro studies have indicated the role 
of multiple CYP isoforms in hemolytic toxicity of PQ 
with predominant involvement of CYP2D6 and CYP3A4 
[10]. Subsequent reports have indicated the failure of PQ 
treatment in individuals with CYP2D6 poor metabolizer 
genotypes [50–52]. 5-Hydroxy metabolite, spontaneously 
converted to 5,6-orthoquinone metabolite, has been 
linked to therapeutic efficacy of PQ [53] as well as other 
8-aminoquinolines namely tafenoquine and NPC1161B 
[54]. Recent in vitro studies with primary human hepato-
cytes and recombinant human CYP2D5 as well as in vivo 
experiments with mice have confirmed the formation of 
5,6-orthoquinone through CYP2D6 mediated pathway 
[20, 21, 53].
The pathway 3 (Fig. 3) involves oxidative deamination 
of PQ at the terminal amine of the aminoalkyl side chain, 
resulting in formation of PQ-aldehyde, PQ alcohol and 
cPQ, which are further metabolized through additional 
phase I hydroxylations and/or phase II glucuronide con-
jugations. Rapid metabolism of PQ through monoamine 
oxidase-mediated oxidative deamination is responsible 
for short half-life of the drug. High circulating concentra-
tions of cPQ, the major metabolite of this pathway, have 
been demonstrated in mouse [31], dog [38], primate [39] 
and human [13] pharmacokinetic studies. This metabo-
lite is fairly rapidly cleared from the circulation in ani-
mals [31, 38, 39], while in humans high plasma levels of 
cPQ are maintained up to 24 h after PQ administration 
[13]. Even though cPQ is generally considered as an inac-
tive and non-toxic metabolite, further metabolism of 
cPQ through phase I CYP-mediated pathways generate 
potential reactive ring hydroxylated metabolites and qui-
none-imine metabolites. Formation of ring-hydroxylated 
and quinone-imine metabolites of cPQ has also been 
demonstrated in vitro using primary human hepatocytes 
[18, 20]. The significance of these is not yet clear, but 
should be considered in interpretation of future studies.
This study presents the most comprehensive plasma 
and urinary metabolite profile of PQ in humans to date. 
The structures of metabolites were predicted on the 
basis of LC- profile, accurate mass and mass fragmen-
tation patterns [18, 21, 22]. Identity of selected criti-
cal metabolites was also confirmed with the chemically 
synthesized standards [21, 22]. PQ is currently under 
large numbers of clinical trials in different populations 
in various countries, specially directed towards malaria 
control and elimination efforts [40–42]. Recent reports 
have indicated critical importance of pharmacogenetic 
factors, especially the role of CYP2D6 polymorphisms 
in therapeutic outcomes of PQ clinical trials. PQ is pri-
marily used for P. vivax radical cure i.e. prevention of 
malaria relapse [1]. Recent global efforts have resulted in 
significant decline in deaths due to P. falciparum infec-
tions [43–45]. However, cases of P. vivax malaria have 
rather increased in some areas [46, 47]. PQ is also recom-
mended for prevention of transmission of P. falciparum 
due to its activity against mature stage V gametocytes 
[48, 49]. PQ mass drug administration has also been sug-
gested to hold promise in preventing malaria transmis-
sion for malaria control and elimination [40]. The risk of 
haemolytic toxicity of PQ in individuals with genetic defi-
ciency of G6PD, which constitutes a significant propor-
tion in malaria endemic countries, is a major concern [5]. 
Evaluation of PQ metabolite profiles in PQ clinical trials 
should be useful for better understanding of the vari-
able therapeutic and safety profiles. The results reported 
in this paper provide useful baseline data for investigat-
ing PQ metabolite profiles in ongoing and future clini-
cal studies with PQ and other 8-aminoquinolines. Direct 
metabolism of PQ through phase II conjugation path-
way (pathway 1) and oxidative deamination (pathway 3), 
resulting in formation of cPQ as the most predominant 
metabolite, may determine pharmacokinetics and phar-
macodynamics properties of PQ. Short half-life of PQ 
due to its metabolism to cPQ (presumed as an inactive 
metabolite) has been considered as a major limitation of 
PQ and requires 14 days’ long treatment for malaria radi-
cal cure [1]. Clinical trials with shorter 7 days’ treatment 
schedule have mostly yielded inclusive results. This study 
also reports further metabolism of cPQ through phase 
I reactions and requires attention regarding potential 
toxicity of this metabolite. No metabolite has still been 
unequivocally linked to efficacy and/or toxicity of PQ. 
However, besides PQ, determination of key metabolites 
of PQ from each pathway namely PQ N-glucuronide, 
5,6-orthoquinone PQ and cPQ along with genotyping for 
CYP2D6 in PQ clinical trials may help for finding the link 
between PQ metabolism and therapeutic outcomes.
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Conclusion
This is the most exhaustive study on identification and 
characterization of human metabolites of primaquine, 
the only approved drug for malaria radical cure. Based 
on overall metabolites’ profile, three pathways were pre-
dicted for metabolism by humans, (a) direct glucuronide/
glucose/carbamate/acetate conjugation of PQ (b) hydrox-
ylation of PQ at different positions on the quinoline 
ring and (c) oxidative deamination of PQ at the terminal 
amine of the aminoalkyl side chain. Metabolism of PQ 
through direct conjugation and oxidative deamination 
pathways may determine pharmacokinetics and pharma-
codynamics of this important antimalarial drug. Metab-
olism of PQ through hydroxylations on the quinolone 
ring, predictably catalyzed by cytochrome  P450 (CYP2D6) 
mediated pathways, generates monohydroxylated PQ 
metabolites. These metabolites have been implicated in 
therapeutic efficacy and hemolytic toxicity of PQ. Fur-
ther, extension of these studies to quantitative profiling 
of key metabolites in malaria infected individuals treated 
with PQ and their correlation with therapeutic outcomes 
vis-à-vis CYP2D6 genotypes may be useful in determin-
ing the rational approach for application of PQ in malaria 
radical cure, the primary application of this drug, as well 
as malaria control programs.
Additional file
Additional file 1: Fig. 1S. Key fragments of PQ and other metabolites 
using LC/ESI‑QToF
Abbreviations
PQ: primaquine; cPQ: carboxyprimaquine; UHPLC‑QToF‑MS: ultra high‑perfor‑
mance liquid chromatography coupled with high‑resolution mass spectro‑
metric; G6PD: glucose 6‑phosphate dehydrogenase; HRMS: high resolution 
mass spectrometry.
Authors’ contributions
BLT and LAW participated in research design; BA, BLT, NDC, PSF and YHW 
performed the experiments; NPDN, HMTBH, SIK and IAK contributed new 
reagents or analytical tools; BA, BLT, NDC, PSF, NPDN, YHW, MAE, JDM, PAZ and 
LAW performed data analysis; BA, BLT, NDC, PSF, NPDN, YHW, JYB, SIK, MAE, 
JDM, PAZ and LAW wrote or contributed to the writing of the manuscript. All 
authors read and approved the final manuscript.
Author details
1 National Center for Natural Products Research, School of Pharmacy, The 
University of Mississippi, University, MS 38677, USA. 2 Ironstone Separations, 
Inc., 147 CR 245, Etta, MS 38627, USA. 3 Center for Global Health & Diseases, 
Case Western Reserve University Cleveland, Ohio 44106, USA. 
Acknowledgements
The authors thank Dr. David Jollow, Medical University of South Carolina, 
retired, for his continuing input and advice and help in interpretation. The 
views, opinions and/or findings contained in this presentation are those of 
the author(s) and do not necessarily reflect the views of the US Department of 
Defense and should not be construed as an official DoD/Army position, policy 
or decision unless so designated by other documentation. No official endorse‑
ment should be made.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The data generated during this study are included in this published article and 
the supplementary information files.
Ethical approval and consent to participate
This study was conducted at the Department of Student & Employees Health 
Services, The University of Mississippi, under the supervision of Dr. Travis W. 
Yates (MD), following a protocol approved by the IRB (The University of Mis‑
sissippi IRB file number 2010–0013). No identifier is included in this report and 
written consents were obtained from all the individuals participated in this 
study.
Funding
Development of LC–MS/MS analytical methods and synthesis of PQ 
metabolites standards were supported by grants from the US Army Medi‑
cal Research & Materiel Command Awards Nos. W81XWH‑13‑2‑0026 and 
W81XWH‑15‑1‑0704 to the University of Mississippi. This study was supported 
in part by the Bill & Melinda Gates Foundation through a Grand Challenge 
Award [OPP53288] to BLT & LAW.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 28 April 2018   Accepted: 30 July 2018
References
 1. Galappaththy GNL, Tharyan P, Kirubakaran R. Primaquine for preventing 
relapse in people with Plasmodium vivax malaria treated with chloro‑
quine. Cochrane Database Syst Rev. 2013. https ://doi.org/10.1002/14651 
858.CD004 389.pub3.
 2. Graves PM, Choi L, Gelband H, Garner P. Primaquine or other 8‑aminoqui‑
noline for reducing P. falciparum transmission. Cochrane Database Syst 
Rev. 2018. https ://doi.org/10.1002/14651 858.CD008 152.pub5.
 3. White NJ. Primaquine to prevent transmission of falciparum malaria. 
Lancet Infect Dis. 2013;13:175–81.
 4. Tekwani BL, Walker LA. 8‑Aminoquinolines: future role as antiprotozoal 
drugs. Curr Opin Infect Dis. 2006;19:623–31.
 5. Uthman OA, Graves PM, Saunders R, Gelband H, Richardson M, Garner P. 
Safety of primaquine given to people with G6PD deficiency: systematic 
review of prospective studies. Malar J. 2017;16:346.
 6. Watson J, Taylor WR, Menard D, Kheng S, White NJ. Modelling pri‑
maquine‑induced haemolysis in G6PD deficiency. eLife. 2017;6:e23061.
 7. Gómez‑Manzo S, Marcial‑Quino J, Vanoye‑Carlo A, Serrano‑Posada H, 
Ortega‑Cuellar D, González‑Valdez A, et al. Glucose‑6‑phosphate dehy‑
drogenase: update and analysis of new mutations around the world. Int J 
Mol Sci. 2016;17:2069.
 8. Luzzatto L, Nannelli C, Notaro R. Glucose‑6‑phosphate dehydrogenase 
deficiency. Hematol Oncol Clin N Am. 2016;30:373–93.
 9. Mbanefo EC, Ahmed AM, Titouna A, Elmaraezy A, Trang NTH, Long NP, 
et al. Association of glucose‑6‑phosphate dehydrogenase deficiency and 
malaria: a systematic review and meta‑analysis. Sci Rep. 2017;7:45963.
 10. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome 
 P450‑dependent toxic effects of primaquine on human erythrocytes. 
Toxicol Appl Pharmacol. 2009;241:14–22.
 11. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL. Understanding 
the mechanisms for metabolism‑linked hemolytic toxicity of primaquine 
against glucose 6‑phosphate dehydrogenase deficient human erythro‑
cytes: evaluation of eryptotic pathway. Toxicology. 2012;294:54–60.
 12. Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the con‑
text of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol 
Ther. 2016;161:1–10.
Page 14 of 14Avula et al. Malar J  (2018) 17:294 
 13. Tekwani BL, Avula B, Sahu R, Chaurasiya ND, Khan SI, Jain S, et al. Enanti‑
oselective pharmacokinetics of primaquine in healthy human volunteers. 
Drug Metab Dispos. 2015;43:571–7.
 14. Baird JK. Davidson DE Jr, Decker‑Jackson JE. Oxidative activity of 
hydroxylated primaquine analogs: non‑toxicity to glucose‑6‑phosphate 
dehydrogenase‑deficient human red blood cells in vitro. Biochem Phar‑
macol. 1986;35:1091–8.
 15. Fletcher KA, Barton PF, Kelly JA. Studies on the mechanisms of oxidation 
in the erythrocyte by metabolites of primaquine. Biochem Pharmacol. 
1988;37:2683–90.
 16. Bolchoz LJ, Budinsky RA, McMillan DC, Jollow DJ. Primaquine‑induced 
hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine 
metabolite 6‑methoxy‑8‑hydroxylaminoquinoline. J Pharmacol Exp Ther. 
2001;297:509–15.
 17. Bowman ZS, Oatis JE, Whelan JL, Jollow DJ, McMillan DC. Primaquine‑
induced hemolytic anemia: susceptibility of normal versus glutathione‑
depleted rat erythrocytes to 5‑hydroxyprimaquine. J Pharmacol Exp Ther. 
2004;309:79–85.
 18. Avula B, Tekwani BL, Chaurasiya ND, Nanayakkara N, Wang YH, Khan SI, 
et al. Profiling primaquine metabolites in primary human hepatocytes 
using UHPLC‑QTOF‑MS with 13C stable isotope labeling. J Mass Spec‑
trom. 2013;48:276–85.
 19. Jin X, Pybus B, Marcsisin S, Logan T, Luong T, Sousa J, et al. An LC–MS 
based study of the metabolic profile of primaquine, an 8‑aminoquinoline 
antiparasitic drug, with an in vitro primary human hepatocyte culture 
model. Eur J Drug Metab Pharmacokinet. 2014;39:139–46.
 20. Fasinu PS, Avula B, Tekwani BL, Nanayakkara ND, Wang Y‑H, Herath HB, 
et al. Differential kinetic profiles and metabolism of primaquine enanti‑
omers by human hepatocytes. Malar J. 2016;15:224.
 21. Fasinu PS, Tekwani BL, Nanayakkara ND, Avula B, Herath HB, Wang Y‑H, 
et al. Enantioselective metabolism of primaquine by human CYP2D6. 
Malar J. 2014;13:507.
 22. Fasinu PS, Tekwani BL, Avula B, Chaurasiya ND, Nanayakkara ND, Wang 
Y‑H, et al. Pathway‑specific inhibition of primaquine metabolism by 
chloroquine/quinine. Malar J. 2016;15:466.
 23. Mihaly G, Ward S, Edwards G, Orme M, Breckenridge A. Pharmacokinetics 
of primaquine in man: identification of the carboxylic acid derivative as a 
major plasma metabolite. Br J Clin Pharmacol. 1984;17:441–6.
 24. Frischer H, Mellovitz R, Ahmad T, Nora M. The conversion of primaquine 
into primaquine‑aldehyde, primaquine‑alcohol, and carboxyprimaquine, 
a major plasma metabolite. J Lab Clin Med. 1991;117:468–76.
 25. Bangchang KN, Songsaeng W, Thanavibul A, Choroenlarp P, Karbwang 
J. Pharmacokinetics of primaquine in G6PD deficient and G6PD normal 
patients with vivax malaria. Trans R Soc Trop Med Hyg. 1994;88:220–2.
 26. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH, et al. Does 
gender, food or grapefruit juice alter the pharmacokinetics of primaquine 
in healthy subjects? Br J Clin Pharmacol. 2006;61:682–9.
 27. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri 
S, Lee SJ, et al. Pharmacokinetic interactions between primaquine and 
chloroquine. Antimicrob Agents Chemother. 2014;58:3354–9.
 28. Lal J, Mehrotra N, Gupta RC. Analysis and pharmacokinetics of bulaquine 
and its major metabolite primaquine in rabbits using an LC‑UV 
method—a pilot study. J Pharm Biomed Anal. 2003;32:141–50.
 29. Dwivedi A, Saxena D, Singh S. HPLC and HPTLC assays for the antimalarial 
agents chloroquine, primaquine and bulaquine. J Pharm Biomed Anal. 
2003;33:851–8.
 30. Sinha SN, Dua VK. Fast atom bombardment mass spectral analysis of 
three new oxidative products of primaquine. Int J Mass Spectrom. 
2004;232:151–63.
 31. Avula B, Khan SI, Tekwani BL, Dhammika Nanayakkara N, McChesney JD, 
Walker LA, et al. Analysis of primaquine and its metabolite carboxypri‑
maquine in biological samples: enantiomeric separation, method valida‑
tion and quantification. Biomed Chromatogr. 2011;25:1010–7.
 32. McChesney JD, Sarangan S. Synthesis of 8‑(3‑carboxy‑l‑methyl‑
propylammo)‑6‑methoxyquinoline: a newly characterized primaquine 
metabolite. Pharm Res. 1984;1:96–8.
 33. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar 
J. 2014;13:418.
 34. Sadeque AJ, Usmani KA, Palamar S, Cerny MA, Chen WG. Identification of 
human UDP‑glucuronosyltransferases involved in N‑carbamoyl glucuro‑
nidation of lorcaserin. Drug Metab Dispos. 2012;40:772–8.
 35. Du Y‑L, Dalisay DS, Andersen RJ, Ryan KS. N‑carbamoylation of 2, 4‑diam‑
inobutyrate reroutes the outcome in padanamide biosynthesis. Chem 
Biol. 2013;20:1002–11. https ://doi.org/10.1016/j.chemb iol.2013.06.013.
 36. Gunduz M, Argikar UA, Baeschlin D, Ferreira S, Hosagrahara V, Harriman 
S. Identification of a novel N‑carbamoyl glucuronide: in vitro, in vivo, and 
mechanistic studies. Drug Metab Dispos. 2010;38:361–7.
 37. Potter BM, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, et al. Differential 
CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob 
Agents Chemother. 2015;59:2380–7.
 38. Nanayakkara ND, Tekwani BL, Herath HB, Sahu R, Gettayacamin M, 
Tungtaeng A, et al. Scalable preparation and differential pharmacologic 
and toxicologic profiles of primaquine enantiomers. Antimicrob Agents 
Chemother. 2014;58:4737–44.
 39. Saunders D, Vanachayangkul P, Imerbsin R, Khemawoot P, Siripokasupkul 
R, Tekwani BL, et al. Pharmacokinetics and pharmacodynamics of (+)‑pri‑
maquine and (−)‑primaquine enantiomers in rhesus macaques (Macaca 
mulatta). Antimicrob Agents Chemother. 2014;58:7283–91.
 40. Hayes DJ, Banda CG, Chipasula‑Teleka A, Terlouw DJ. Modelling the 
therapeutic dose range of single low dose primaquine to reduce malaria 
transmission through age‑based dosing. BMC Infect Dis. 2017;17:254.
 41. Lin JT, Lon C, Spring MD, Sok S, Chann S, Ittiverakul M, et al. Single dose 
primaquine to reduce gametocyte carriage and Plasmodium falciparum 
transmission in Cambodia: an open‑label randomized trial. PLoS ONE. 
2017;12:e0168702.
 42. Wampfler R, Hofmann NE, Karl S, Betuela I, Kinboro B, Lorry L, et al. Effects 
of liver‑stage clearance by primaquine on gametocyte carriage of Plas-
modium vivax and P. falciparum. PLoS Negl Trop Dis. 2017;11:e0005753.
 43. Daily JP. Malaria 2017: update on the clinical literature and management. 
Curr Infect Dis Rep. 2017;19:28.
 44. Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis 
WC, Wells TNC. Malaria. Nat Rev Dis Primers. 2017;3:17050.
 45. Thu AM, Phyo AP, Landier J, Parker DM, Nosten FH. Combating multi‑drug 
resistant Plasmodium falciparum malaria. FEBS J. 2017;284:2569–78.
 46. Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. 
Expert Rev Anti Infect Ther. 2016;14:885–900.
 47. Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. 
Challenges for achieving safe and effective radical cure of Plasmodium 
vivax: a round table discussion of the APMEN Vivax Working Group. Malar 
J. 2017;16:141.
 48. Warhurst DC. Why are primaquine and other 8‑aminoquinolines particu‑
larly effective against the mature gametocytes and the hypnozoites of 
malaria? Ann Trop Med Parasitol. 1984;78:165.
 49. Butterworth AS, Skinner‑Adams TS, Gardiner DL, Trenholme KR. 
Plasmodium falciparum gametocytes: with a view to a kill. Parasitology. 
2013;140:1718–34.
 50. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Pri‑
maquine failure and cytochrome P‑450 2D6 in Plasmodium vivax malaria. 
J Engl J Med. 2013;369:1381–2.
 51. Brasil LW, Rodrigues‑Soares F, Santoro AB, Almeida ACG, Kühn A, Rama‑
sawmy R, Lacerda MVG, Monteiro WM, Suarez‑Kurtz G. CYP2D6 activity 
and the risk of recurrence of Plasmodium vivax malaria in the Brazilian 
Amazon: a prospective cohort study. Malar J. 2018;17:57.
 52. Baird JK, Battle KE, Howes RE. Primaquine ineligibility in anti‑relapse 
therapy of Plasmodium vivax malaria: the problem of G6PD deficiency 
and cytochrome P‑450 2D6 polymorphis ms. Malar J. 2018;17:42.
 53. Pybus BS, Marcsisin SR, Deye G, Sousa JC, Li Q, Caridha D, et al. The 
metabolism of primaquine to its active metabolite is dependent on CYP 
2D6. Malar J. 2013;12:212.
 54. Vuong C, Xie LH, Potter BM, Zhang J, Zhang P, Duan D, et al. Differential 
cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. 
Antimicrob Agents Chemother. 2015;59:3864–9.
